The Common Painkiller That TRIGGERS Hallucinations

Woman holding a white pill and a glass of water — Photo: fizkes / Shutterstock

Opioid painkillers can produce hallucinations vivid and convincing enough that physicians have mistaken them for schizophrenia — a diagnostic error with consequences that follow a patient for years.

Key Points

A peer-reviewed case report describes a 67-year-old man diagnosed with “schizophrenia, unspecified” whose hallucinations tracked precisely with his use of Norco (hydrocodone/acetaminophen) and vanished once he stopped taking it.
Opioid-induced hallucinations are a recognized, if underreported, clinical phenomenon — documented in review literature and, for tramadol specifically, formally linked by Health Canada’s drug safety office.
Dozens of other common medications, including some over-the-counter analgesics, appear on formal lists of drugs capable of triggering hallucinations.
The broader psychiatric literature treats this as a differential-diagnosis problem — one where chronology and symptom resolution after stopping a drug matter more than the hallucination itself.
Because opioid- and substance-induced psychosis can look identical to schizophrenia on presentation, misdiagnosis is a documented, recurring failure mode in psychiatric practice — not a one-off anomaly.

The Case That Exposed the Problem

The clearest evidence for this claim comes from a case report published in the journal Cureus and archived on PubMed Central, describing a 67-year-old man referred to a psychiatry clinic by his internal medicine provider carrying a diagnosis of “schizophrenia, unspecified”. He had been experiencing auditory and visual hallucinations for two years — voices, visions, the full sensory package that clinicians associate reflexively with primary psychotic illness. What the referring diagnosis missed was timing: the hallucinations had begun coinciding with his use of, and dose increases in, Norco, prescribed for chronic pain.

When his psychiatric team reconstructed the history and discontinued the opioid, the hallucinations stopped. That resolution is the single most important data point in the case, because in psychiatry, a symptom that disappears when you remove its suspected cause is about as close to proof of causation as bedside medicine gets. The authors explicitly framed the case as a warning: opioid-induced hallucinations can mimic schizophrenia closely enough to generate a wrong diagnosis, and hallucinations by themselves — absent a fuller clinical picture — do not establish that a patient has a primary psychotic disorder.

Why Opioids Produce Hallucinations at All

Opioids act on mu-opioid receptors concentrated in the brainstem and limbic structures, regions that also modulate arousal, sensory gating, and dopaminergic signaling — the same dopamine pathways implicated in classic psychotic symptoms. Push those systems hard enough, particularly at escalating doses or in older patients with reduced drug clearance, and the sensory-perceptual machinery can misfire, producing hallucinations that are neurologically real experiences, not imagined ones. A review of the literature on opioid-induced hallucinations found the mechanism plausible but still incompletely mapped, and noted the phenomenon is likely underreported because clinicians and patients alike default to psychiatric explanations rather than pharmacological ones.

Tramadol offers the best-documented example of this mechanism in action. Health Canada’s Summary Safety Review examined reports of hallucinations tied to tramadol-containing products and concluded there was an established link between normal-dose use and visual and auditory hallucinations, particularly in vulnerable patients. A separate systematic review catalogued roughly 1,746 documented cases of tramadol-associated hallucinations and found the underlying mechanism likely involves multiple receptor systems beyond the opioid pathway itself, which is consistent with why symptoms can appear even at doses well within normal prescribing limits. This is not a fringe or exotic reaction; it is a recognized, if statistically uncommon, adverse effect with a regulatory paper trail behind it.

A Wider List Than Most Patients Realize

Opioids are not alone on this list. A compiled appendix of medications associated with visual hallucinations as a side effect includes several analgesics and anti-inflammatory drugs that patients would never think to suspect, including ibuprofen and acetaminophen in certain contexts. The FDA’s own labeling database catalogs hallucinations as a listed side effect across a range of approved drugs, some far removed from psychiatry or pain management. The pattern across all of these cases is consistent: a drug alters neurotransmitter activity, sedation, or metabolic balance enough to disrupt normal sensory processing, and the resulting hallucination looks, to an untrained eye, indistinguishable from one caused by mental illness.

Why This Gets Misdiagnosed So Often

The deeper issue is not that opioids can cause hallucinations — that much is established and unsurprising to anyone versed in pharmacology. The issue is how easily that fact gets lost in a psychiatric intake. Research on hallucination characteristics across conditions has found that no single feature of a hallucination reliably distinguishes a drug-induced episode from a schizophrenic one, with the narrow exception of age of onset in late adolescence. A hallucination in a 67-year-old man on opioids and a hallucination in a 22-year-old with prodromal schizophrenia can sound, on description, nearly identical. What differs is context: medication history, timing relative to dose changes, and — critically — whether the symptom resolves after the suspected drug is withdrawn.

This is precisely the failure mode documented elsewhere in psychiatric literature. Johns Hopkins clinicians have separately warned that schizophrenia is frequently overdiagnosed in young people specifically because clinicians rely on reported hallucinations alone, without adequately excluding other causes. Older case literature going back decades documents the same error pattern with different substances: a 2002 case report described a woman with a five-year diagnosis of chronic psychotic illness whose hallucinations, on closer inspection, tracked a treatable non-psychiatric cause. The common denominator across these cases spanning twenty years is a diagnostic shortcut — treating hallucination as synonymous with primary mental illness rather than as a symptom with a differential list.

What the Evidence Does Not Show

It is worth being precise about what this body of evidence supports and what it does not. It does not show that Norco, hydrocodone, or opioid painkillers routinely cause schizophrenia-like illness in the general prescribed population; the case reports and safety reviews describe a real but comparatively rare adverse reaction, not a common one. Health Canada, for instance, based its tramadol conclusion on a relatively small number of confirmed reports out of the far larger population of patients using the drug without incident. The clinical consensus instead treats opioid- and substance-induced hallucinations as a differential-diagnosis category — one requiring ruled-out alternatives, careful chronology, and observed symptom resolution — rather than evidence that a common painkiller is secretly a psychosis-inducing agent for most people who take it.

The Practical Takeaway for Patients and Families

For patients, caregivers, and the physicians who treat them, the lesson from this case is procedural rather than alarmist. Any new hallucination that appears alongside a new prescription or a dose change — particularly involving opioids, tramadol, or older adults on multiple medications — deserves a medication review before it earns a psychiatric label. That review costs little and, as the Cureus case demonstrated, can spare a patient years of an inaccurate diagnosis, unnecessary antipsychotic treatment, and the social and medical consequences that follow a “schizophrenia, unspecified” chart entry that never should have been written in the first place.